Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: Preliminary analyses

Nuclear Medicine and Biology

Volumn 27, Issue 5, 2000, Pages 523-527

  Martinez, Diana ^a   Mawlawi, Osama ^a   Hwang, Dah Ren ^a   Kent, Justine ^a   Simpson, Norman ^a   Parsey, Ramin V ^a   Hashimoto, Tomoki ^a   Slifstein, Mark ^a   Huang, Yiyun ^a   Van Heertum, Ronald ^a   Abi Dargham, Anissa ^a   Caltabiano, Stephen ^b   Malizia, Andrea ^b   Cowley, Hugh ^b   Mann, J John ^a   Laruelle, Marc ^a  

^a Columbia Univ Coll Phys Surgs D ^*  (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

5 HT(1A) receptors; 11C WAY 100635; Mood disorders; Pindolol; Positron emission tomography; SSRI

Indexed keywords

AUTORECEPTOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; PINDOLOL; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DEPRESSION; DISTRIBUTION VOLUME; DRUG RECEPTOR BINDING; HUMAN; IMAGE ANALYSIS; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY;

ADULT; BRAIN CHEMISTRY; HUMANS; MALE; MIDDLE AGED; PINDOLOL; RAPHE NUCLEI; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 18144447956     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(00)00122-0     Document Type: Article

References (44)

1. 11C]NNC 112 in humans: Validation and reproducibility. J. Cereb. Blood Flow Metab. 20225-243.
2. 1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl.). 144:1999;303-305.
3. Artigas F., Perez V., Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry. 51:1994;248-251.
4. 1A antagonists. Trends Neurosci. 19:1996;378-383.
5. Bakish D., Hooper C.L., Thornton M.D., Wiens A., Miller C.A., Thibaudeau C.A. Fast onset An open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy . Int. Clin. Psychopharmacol. 12:1997;91-97.
6. Berman R.M., Anand A., Cappiello A., Miller H.L., Hu X.S., Oren D.A., Charney D.S. The use of pindolol with fluoxetine in the treatment of major depression Final results from a double-blind, placebo-controlled trial . Biol. Psychiatry. 45:1999;1170-1177.
7. Berman R.M., Darnell A.M., Miller H.L., Anand A., Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression A double-blind, placebo-controlled trial . Am. J. Psychiatry. 154:1997;37-43.
8. Blier P., Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J. Clin. Psychopharmacol. 15:1995;217-222.
9. Blier P., de Montigny C. Serotoninergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience. 16:1985;949-955.
10. Blier P., de Montigny C. Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:1994;220-226.
11. Bordet R., Thomas P. and Dupuis B. (1998) Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial. Reseau de Recherche et d'Experimentation Psychopharmacologique Am. J. Psychiatry 155, 1346-1351.
12. Chaput Y., de Montigny C., Blier P. Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors Electrophysiological studies in the rat brain . Naunyn Schmiedebergs Arch. Pharmacol. 333:1986;342-348.
13. 1A receptors. Neurochem. Res. 21:1996;557-562.
14. Drevets W., Frank E., Price J., Kupfer D., Holt D., Greer P. J., Huang Y., Gautier C. and Mathis C. (1999) PET imaging of serotonin 1A receptor binding in depression. Biol. Psychiatry 1375-1387.
15. Duvernoy H. (1991) The Human Brain. Surface, Three-Dimensional Sectional Anatomy and MRI. Sringer-Verlag Wien, New York.
16. Farde L., Ito H., Swahn C.G., Pike V.W., Halldin C. Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. J. Nucl. Med. 39:1998;1965-1971.
17. 1A receptor antagonist, WAY-100635. Eur. J. Pharmacol. 281:1995;81-88.
18. Gartside S.E., Clifford E.M., Cowen P.J., Sharp T. Effects of (-)-tertatolol, (-)-penbutolol and (+/-)-pindolol in combination with paroxetine on presynaptic 5-HT function An in vivo microdialysis and electrophysiological study . Br. J. Pharmacol. 127:1999;145-152.
19. 1A receptors in rat brain membranes. Eur. J. Pharmacol. 288:1995;173-186.
20. 11C]WAY-100635 for PET. Neuroimage. 8:1998;426-440.
21. Hjorth S. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur. J. Pharmacol. 303:1996;183-186.
22. Hoyer D., Schoeffter P. 5-HT receptors Subtypes and second messengers . J. Recept. Res. 11:1991;197-214.
23. 11C-carbonyl]WAY-100635. Nucl. Med. Biol. 26:1999;815-819.
24. Invernizzi R., Belli S., Samanin R. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res. 584:1992;322-324.
25. Kates W.R., Abrams M.T., Kaufmann W.E., Breiter S.N., Reiss A.L. Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome. Psychiat. Res. Neuroimag. 75:1997;31-48.
26. Killiany R.J., Moss M.B., Nicholson T., Jolez F., Sandor T. An interactive procedure for extracting features of the brain from magnetic resonance images The lobes . Human Brain Mapping. 5:1997;355-363.
27. 2 receptors in healthy subjects. J. Nucl. Med. 35:1994;743-754.
28. Maes M., Libbrecht I., van Hunsel F., Campens D., Meltzer H.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19:1999;177-182.
29. Maes M., Vandoolaeghe E., Desnyder R. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. J. Affect. Disord. 41:1996;201-210.
30. Maione S., Palazzo E., Pallotta M., Leyva J., Berrino L., Rossi F. Effects of imipramine on raphe nuclei and prefrontal cortex extracellular serotonin levels in the rat. Psychopharmacology (Berl.). 134:1997;401-405.
31. Mintun M.A., Raichle M.E., Kilbourn M.R., Wooten G.F., Welch M.J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 15:1984;217-227.
32. 11C]WAY-100635, in monkey and human plasma by HPLC Comparison of the behavior of an identified radioactive metabolite with parent radioligand in monkey using PET . Nucl. Med. Biol. 23:1996;627-634.
33. 11C-Carbonyl]-WAY100635 binding potential measurement in humans. J. Cereb. Blood Flow Metab. in press.
34. Parsey R. V., Kegeles L., Hwang D. R., Simpson N., Abi-Dargham A., Mawlawi O., Sfistein M., Van Heertum R., Mann J. J. and Laruelle M. (2000) Quantification of brain serotonin transporters in humans with (+) and (-)McNeil 5652. J. Nucl. Med. in press.
35. Perez V., Gilaberte I., Faries D., Alvarez E., Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet. 349:1997;1594-1597.
36. Perez V., Soler J., Puigdemont D., Alvarez E., Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch. Gen. Psychiatry. 56:1999;375-379.
37. 11C]WAY-100635. Eur. J. Pharmacol. 301:1995;R5-R7.
38. 11C]WAY-100635 PET study. Neuropsychopharmacology in press.
39. 1A receptors In vivo microdialysis and electrophysiological studies in the rat brain . Neuropsychopharmacology. 15:1996;349-360.
40. Talairach J. and Tournoux P. (1988) Co-Planar Stereotactic Atlas of the Human Brain. Three-Dimensional Proportional System: An Approach of Cerebral Imaging. Theime Medical Publisher, New York.
41. Tome M.B., Isaac M.T., Harte R., Holland C. Paroxetine and pindolol A randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency . Int. Clin. Psychopharmacol. 12:1997;81-89.
42. Woods R.P., Cherry S.R., Mazziotta J.C. Rapid automated algorithm for aligning and reslicing PET images. J. Comp. Assist. Tomog. 16:(4):1992;620-633.
43. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response? J. Clin. Psychopharmacol. 17:1997;446-450.
44. Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression A controlled study . J. Clin. Psychopharmacol. 18:1998;441-446.